Protara Therapeutics, Inc.
1 Little West 12th Street
New York, New York 10014
(646) 844-0337
May 21, 2020
Via Edgar
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Abby Adams
Re: | Protara Therapeutics, Inc. |
Registration Statement on Form S-3
File No. 333-238273
Acceleration Request
Requested Date: Tuesday, May 26, 2020
Requested Time: 4:30 p.m. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Protara Therapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-238273) (the “Registration Statement”) to become effective at 4:30 p.m. Eastern Time on Tuesday, May 26, 2020, or as soon thereafter as is practicable. The Registrant also hereby requests a copy of the written order verifying the effective date.
Once the Registration Statement has been declared effective, please orally confirm that event with Ryan S. Sansom of Cooley LLP, at (617) 937-2335 or Karen Elizabeth Deschaine of Cooley LLP at (858) 550-6088.
Sincerely,
Protara Therapeutics, Inc.
By: | /s/ Blaine Davis |
Blaine Davis
Chief Financial Officer